210 related articles for article (PubMed ID: 36205204)
1. Pilot study of safety and efficacy of topical liposomal amphotericin B for cutaneous leishmaniasis caused by Leishmania major in Islamic Republic of Iran.
Khamesipour A; Mohammadi A; Jaafari M; Eskandari S; Tasbihi M; Javadi A; Afshari F; Mortazavi H; Firooz A
East Mediterr Health J; 2022 Sep; 28(9):658-663. PubMed ID: 36205204
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Meglumine Antimoniate and Miltefosine in Cutaneous Leishmaniasis.
Rahman A; Tahir M; Naveed T; Abdullah M; Qayyum N; Malik DH; Amin B
J Coll Physicians Surg Pak; 2023 Dec; 33(12):1367-1371. PubMed ID: 38062590
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis.
Solomon M; Ollech A; Pavlotsky F; Barzilai A; Schwartz E; Baum S; Astman N
Acta Derm Venereol; 2024 Apr; 104():adv35089. PubMed ID: 38682801
[TBL] [Abstract][Full Text] [Related]
4. Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B.
Spinicci M; Zammarchi L; Gramiccia M; Di Muccio T; Bartolozzi D; Corsi P; Trotta M; Bartoloni A
J Travel Med; 2021 Aug; 28(6):. PubMed ID: 32918547
[No Abstract] [Full Text] [Related]
5. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
Munir A; Janjua SA; Hussain I
Acta Dermatovenerol Croat; 2008; 16(2):60-4. PubMed ID: 18541100
[TBL] [Abstract][Full Text] [Related]
6. Field Efficacy of Topical Nano-Liposomal Amphotericin B (Sina Ampholeish®) Alone or in Combination with Glucantime® and Cryotherapy on Human Cutaneous Leishmaniasis.
Alizadeh Z; Shirzadi MR; Hassanpour GR; Keshavarz H; Mohebali F; Eskandari SE; Zeinali M; Shirmohammad S; Mohebali M
Iran J Parasitol; 2023; 18(4):419-426. PubMed ID: 38169758
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
Asilian A; Sadeghinia A; Faghihi G; Momeni A
Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial.
Javadi A; Khamesipour A; Ghoorchi M; Bahrami M; Khatami A; Sharifi I; Eskandari SE; Fekri A; Aflatoonian MR; Firooz A
PLoS Negl Trop Dis; 2022 Jul; 16(7):e0010569. PubMed ID: 35802749
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial.
Machado PRL; Ribeiro CS; França-Costa J; Dourado MEF; Trinconi CT; Yokoyama-Yasunaka JKU; Malta-Santos H; Borges VM; Carvalho EM; Uliana SRB
Trop Med Int Health; 2018 Sep; 23(9):936-942. PubMed ID: 29924907
[TBL] [Abstract][Full Text] [Related]
10. Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis.
Rajabi O; Layegh P; Hashemzadeh S; Khoddami M
Dermatol Ther; 2016 Sep; 29(5):358-363. PubMed ID: 27073044
[TBL] [Abstract][Full Text] [Related]
11. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis.
Mohammad N; Sagheer F; Paracha MM; Khan AQ; Naseem S; Wasim M
J Ayub Med Coll Abbottabad; 2022; 34(4):849-853. PubMed ID: 36566412
[TBL] [Abstract][Full Text] [Related]
12. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
13. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
[TBL] [Abstract][Full Text] [Related]
14. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
Shazad B; Abbaszadeh B; Khamesipour A
Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
[TBL] [Abstract][Full Text] [Related]
15. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran.
Karamian M; Bojd MS; Salehabadi A; Hemmati M; Barati DA
East Mediterr Health J; 2015 Jun; 21(4):280-6. PubMed ID: 26077523
[TBL] [Abstract][Full Text] [Related]
17. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
18. Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran.
Aflatoonian MR; Sharifi I; Aflatoonian B; Bamorovat M; Heshmatkhah A; Babaei Z; Ghasemi Nejad Almani P; Mohammadi MA; Salarkia E; Aghaei Afshar A; Sharifi H; Sharifi F; Khosravi A; Khatami M; Arefinia N; Fekri A; Farajzadeh S; Khamesipour A; Mohebali M; Gouya MM; Shirzadi MR; Varma RS
PLoS Negl Trop Dis; 2019 Jun; 13(6):e0007423. PubMed ID: 31188834
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
Faghihi G; Tavakoli-kia R
Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
[TBL] [Abstract][Full Text] [Related]
20. Treatment of imported New World cutaneous leishmaniasis in Germany.
Harms G; Scherbaum H; Reiter-Owona I; Stich A; Richter J
Int J Dermatol; 2011 Nov; 50(11):1336-1342. PubMed ID: 22004484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
